Chinese University of Hong Kong
cuhk.edu.hkLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,420
Active
445
Phase 3
92
Total enrollment
1,079,196
Pipeline matrix
Showing 40 of 82 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisolone | — | — | — | — | 2 | ||
| 0.5% levobupivacaine | — | — | — | — | 2 | ||
| Esomeprazole | — | — | — | — | 4 | ||
| Misoprostol | — | — | — | — | 2 | ||
| RSV vaccination | — | — | — | — | — | 1 | |
| maraviroc | — | — | — | — | — | 1 | |
| Semaglutide 0.5 mg | — | — | — | — | — | 1 | |
| Semaglutide 1.0 mg | — | — | — | — | — | 1 | |
| Semaglutide 0.25 mg | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Baricitinib 4 MG | — | — | — | — | — | 1 | |
| Finerenone | — | — | — | — | — | 1 | |
| Trazodone | — | — | — | — | — | 1 | |
| 2% Xylocaine with adrenaline 1:200,000 | — | — | — | — | — | 1 | |
| Bisacodyl 5 mg | — | — | — | — | — | 1 | |
| Carvedilol | — | — | — | — | — | 1 | |
| Hydrochlorothiazide 25mg once per day | — | — | — | — | — | 1 | |
| Amgevita 40Mg Solution for | — | — | — | — | — | 1 | |
| DoxyODPrEP | — | — | — | — | — | 1 | |
| DoxyPEP | — | — | — | — | — | 1 | |
| Vonoprazan | — | — | — | — | — | 1 | |
| Riociguat | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | 2 | ||
| Methadone | — | — | — | — | — | 2 | |
| Morphine | — | — | — | — | — | 2 | |
| Chinese Herbal Medicine granules | — | — | — | — | — | 1 | |
| 5-FU, Leucovorin, Oxaliplatin, Docetaxel | — | — | — | — | — | 1 | |
| XELOX | — | — | — | — | — | 1 | |
| Indomethacin | — | — | — | — | — | 1 | |
| 4CMenB vaccine | — | — | — | — | — | 1 | |
| Tissue Plasminogen Activator | — | — | — | — | — | 1 | |
| Antibiotics first | — | — | — | — | — | 1 | |
| talc powder | — | — | — | — | — | 1 | |
| patient's own venous blood | — | — | — | — | — | 1 | |
| Aspirin 80mg | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | — | 3 | |
| Capecitabine | — | — | — | — | — | 2 | |
| Empagliflozin 10 MG | — | — | — | — | 2 | ||
| Dorzagliatin | — | — | — | — | — | 3 | |
| Sacituzumab Govitecan | — | — | — | — | — | 1 |
42 more active programs hidden
Next readouts
- 2024-12-01
- 2024-12-31
- 2025-01-25
- 2025-05-02
- 2025-08-18
- 2025-08-31
- 2025-09-30
- 2025-12-21
- 2025-12-31
- 2025-12-31
Top conditions
- Stroke43
- Prostate Cancer35
- Depression28
- Colorectal Cancer22
- Hypertension20
- Obstructive Sleep Apnea19
- Hepatocellular Carcinoma17
- Insomnia16
Frequently asked questions about Chinese University of Hong Kong
- How many clinical trials does Chinese University of Hong Kong have on ClinicalTrials.gov?
- Chinese University of Hong Kong is listed as the lead sponsor on 1,420 clinical trials in ClinicalTrials.gov, 445 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chinese University of Hong Kong's trials are in Phase 3?
- 92 of Chinese University of Hong Kong's trials are in Phase 3, spread across 82 active drug programs.
- What therapeutic areas does Chinese University of Hong Kong focus on?
- Chinese University of Hong Kong's most-studied conditions on ClinicalTrials.gov are Stroke, Prostate Cancer, Depression, Colorectal Cancer, Hypertension.
- When are Chinese University of Hong Kong's next clinical trial readouts?
- Chinese University of Hong Kong has 10 upcoming primary-completion readouts tracked here; the soonest is “Intravenous Methadone for Sternotomy Pain Control in Cardiac Surgery”, expected around 2024-12-01.